Piri Keşif Aracı

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2017.01.023

ISSN: 2013-2514
Cilt: 37
Sayı: 1
Sayfa: 100 - 101

Sınıflandırma :

Tıp ve Halk Sağlığı %91

Pediatri %82

2

Crateriform plaques in a patient with end-stage renal disease. The case of an acquired reactive perforating collagenosis

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Uriel Villela-Segura , Alessandra Irais Miranda-Aguirre , Lorena Estrada-Aguilar

Yıl :

2020

Nefrología (English Edition)

Ek Bilgiler

ISSN: 2013-2514
Cilt: 40
Sayı: 3
Sayfa: 358 - 360

Sınıflandırma :

Tıp ve Halk Sağlığı %94

Nefroloji %63

Dermatoloji %21

3

Impact of first year renal replacement therapy on the hospital admissions of a regional public health system

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Paula Lopez-Sanchez , Jose Portolés , Leyre Martín Rodríguez , Fernando Tornero , Arturo Jose Ramos Martin-Vegue , Jose Antonio Herrero , Juan Luis Cruz Bermúdez

Yıl :

2019

Nefrología (English Edition)

Özet Ek Bilgiler

Introduction and objectives: Chronic kidney disease has a high prevalence and economic impact, and an increased risk of hospitalization. Although there are public regional and country registries, we have not found references to estimate the impact of renal replacement therapy (RRT) on hospital admissions. Methods: We obtained authorization from the ethics committee and health authorities to integrate the REMER [Madrid Kidney Disease Registry] (2013-2014) and Minimum Basic Data Set (2013-2015) databases and to analyze the admissions during the first year of RRT. Results: 767 patients started RRT in all the hospitals of our region across all RRT modalities. More than a third of the patients start dialysis during a hospital admission. This unplanned start, more common in HD than PD, shows relevant differences in patient profile or admission characteristics.Without considering this initial episode, almost 60% of patients were admitted during their first year. The hospitalization rate was 1.2 admissions/patient, higher in HD than in TX or PD; the mean length of stay was 8.6 days.The estimated cost of admissions during the first year is €12,006/patient. Our analysis ensures the exhaustive inclusion of all episodes and accurate estimation based on the discharge form. Conclusion: The impact of RRT on hospitals has been underestimated and is very relevant when calculating the total cost of RRT. Results from other countries cannot be extrapolated due to differences in the health system and patient profile. The integration of clinical databases could open up an opportunity that needs only institutional support for its development. Resumen: Introducción: y objetivos La enfermedad renal crónica tiene una alta prevalencia y coste, así como un mayor riesgo de ingreso. Disponemos de registros públicos y obligatorios, pero no hay referencias recientes para estimar el impacto que el tratamiento sustitutivo renal (TSR) tiene en la actividad hospitalaria. Métodos: Tras las autorizaciones pertinentes, hemos integrado las bases de datos REMER (2013-2014) y CMBDH (2013-2015) para analizar la actividad hospitalaria durante el primer año de TSR. Resultados: Un total de 767 pacientes iniciaron TSR en los 7 hospitales de tercer nivel de la Comunidad de Madrid. Más de una tercera parte lo hicieron de forma no programada durante un ingreso. Este inicio es más frecuente en HD que en DP, pero existen diferencias clínicas relevantes en edad y en comorbilidad. Descartando este primer episodio, casi el 60% de pacientes ingresan durante el primer año. La tasa de ingreso es de 1,2 ingresos/paciente, más alta en HD que en TX y DP; la estancia media es de 8,6 días. El coste agregado de los ingresos del primer año es de 12.006 €/paciente. Nuestro análisis asegura la inclusión exhaustiva de todos los episodios y la estimación precisa de costes. Conclusiones: El impacto del TSR en la actividad hospitalaria ha sido infraestimado y es una parte importante del coste global del TSR. Los resultados de la literatura internacional no pueden extrapolarse a nuestro país por las diferencias en el modelo sanitario y perfil de paciente. La integración de bases de datos clínicas es técnicamente viable y podría abrir una vía inmensa de información que solo requiere apoyo institucional para su desarrollo. Keywords: Renal replacement therapy, Hospital admission, Economic impact, Peritoneal dialysis, Haemodialysis, Transplant, Minimum Basic Data Set, Palabras clave: terapia sustitutiva renal, ingreso hospitalario, coste, diálisis peritoneal, hemodiálisis, trasplante, CMBDH

ISSN: 2013-2514
Cilt: 39
Sayı: 6
Sayfa: 653 - 663

Sınıflandırma :

Nefroloji %97

4

Unlike Kt, high Kt/V is associated with greater mortality: The importance of low V

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Rafael Perez-Garcia , Maite Jaldo , Roberto Alcázar , Patricia de Sequera , Marta Albalate , Marta Puerta , Mayra Ortega , M. Caridad Ruiz , Elena Corchete

Yıl :

2019

Nefrología (English Edition)

Özet Ek Bilgiler

Introduction: Kt/V has been used as a synonym for hemodialysis dose. Patient survival improved with a Kt/V > 1; this target was subsequently increased to 1.2 and 1.3. The HEMO study revealed no significant relationship between Kt/V and mortality. The relationship between Kt/V and mortality often shows a J-shaped curve. Is V the confounding factor in this relationship? The objective of this study is to determine the relationship between mortality and Kt/V, Kt and body water content (V) and lean mass (bioimpedance). Methods: We studied a cohort of 127 prevalent hemodialysis patients, who we followed-up for an average of 36 months. Kt was determined by ionic dialysance, and V and nutrition parameters by bioimpedance. Kt/V, Kt corrected for body surface area (Kt/BSA) and target Kt/BSA were calculated. The mean data from 18,998 sessions were used as hemodialysis parameters, with a mean of 155 sessions per patient. Results: Mean age was 70.4 ± 15.3 years and 61% were male; 76 were dialyzed via an arteriovenous fistula and 65 were on online hemodiafiltration. Weight was 70.6 (16.8) kg; BSA 1.8 (0.25) m2; total body water (V) 32.2 (7.41) l and lean mass index (LMI) 11.1 (2.7) kg/m2. Mean Kt/V was 1.84 (0.44); Kt 56.1(7) l and Kt/BSA 52.8 (10.4) l. The mean target Kt/BSA was 49.7 (4.5) l. Mean Kt/BSA − target Kt/BSA + 6.4 (7.0) l. Patients with a higher Kt/V had worse survival rates than others; with Kt this is not the case. Higher Kt/V values are due to a lower V, with poorer nutrition parameters. LMI and serum albumin were the parameters that best independently predicted the risk of death and are lower in patients with a higher Kt/V and lower V. Conclusion: Kt/V is not useful for determining dialysis doses in patients with low or reduced body water. Kt or the Kt/BSA are proposed as an alternative. Resumen: Introducción: El Kt/V se ha usado como sinónimo de dosis de hemodiálisis. La supervivencia de los pacientes mejoraba con un Kt/V > 1; este objetivo posteriormente fue elevado a 1,2 y a 1,3. En el estudio HEMO no se demostró una relación significativa entre Kt/V y la mortalidad. La relación Kt/V y mortalidad con frecuencia es una curva en «J». ¿Es la V el factor de confusión de esa relación? El objetivo de este estudio es buscar la relación de la mortalidad con el Kt/V, Kt y con el contenido de agua corporal (V) y masa magra (bioimpedancia). Métodos: Se ha estudiado una cohorte de 127 pacientes prevalentes en hemodiálisis seguidos durante una media de 36 meses. Se determinó el Kt por dialisancia iónica y la V y parámetros de nutrición mediante bioimpedancia. Se ha calculado el Kt/V y el Kt alcanzado corregido para superficie corporal (Ktsc) y el Ktsc objetivo. Como parámetros de hemodiálisis se ha utilizado la media de los datos de 18.998 sesiones, con una media de 155 sesiones por paciente. Resultados: La edad media fue 70,4 (15,3) años y un 61% eran hombres; 76 se dializaban mediante fístula arteriovenosa y 65 estaban en HDF-OL. Peso: 70,6 (16,8) kg; superficie corporal: 1,8 (0,25) m2; agua corporal total: 32,2 (7,4) l; índice de masa magra (LTI): 11,1 (2,7) kg/m2. El Kt/V medio fue 1,84 (0,44); Kt: 56,1 (7) l, y el Ktsc, 52,8 (10,4) l. El Ktsc objetivo medio era de 49,7 (4,5) l. La media del Ktsc – Ktsc objetivo: +6,4 (7,0) l. Los pacientes con un Kt/V mayor tienen peor supervivencia que el resto. Con el Kt no existe esta relación. Los Kt/V mayores se deben a una V menor, con peores parámetros de nutrición. La albúmina sérica y el LTI son los parámetros que se relacionan con el riesgo de muerte de forma independiente y son menores en los pacientes con mayor Kt/V y menor V. Conclusión: El Kt/V no es útil para determinar la dosis de diálisis en pacientes con un agua corporal pequeña o disminuida. Se propone el Kt o el Ktsc como alternativa. Keywords: Kt/V, Kt, Hemodialysis, Mortality, Nutrition, Total body water, Palabras clave: Kt/V, Kt, Hemodiálisis, Mortalidad, Nutrición, Agua corporal total

ISSN: 2013-2514
Cilt: 39
Sayı: 1
Sayfa: 58 - 66

Sınıflandırma :

Nefroloji %98

5

Obesity and kidney function; epidemiological study data: Prevalence of chronic kidney disease in Spain. EPIRCE study

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Alfonso Otero González , A.L.M. de Francisco , P. Gayoso , F. Garcia López

Yıl :

2018

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2018.01.001

ISSN: 2013-2514
Cilt: 38
Sayı: 1
Sayfa: 107 - 108

Sınıflandırma :

Nefroloji %90

6

Peritoneal dialysis as a perpetuating cause of hyponatremia

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

José Juan Ribés Cruz , Jose Graña Fandos , Belen Alemany Sánchez , María Aparicio Aliaga , Yaiza Aznar Artiles , Esther Bea Reyes , Yolanda Blanco Mateos , Martina Mravcova , Diego Rodriguez Ortega , Miguel Ángel Candel Rosell

Yıl :

2017

Nefrología (English Edition)

Ek Bilgiler

ISSN: 2013-2514
Cilt: 37
Sayı: 6
Sayfa: 659 - 660

Sınıflandırma :

Nefroloji %100

7

Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Borja Quiroga , Antonio de Santos , David Sapiencia , Yamila Saharaui , Vicente Álvarez-chiva

Yıl :

2019

Nefrología (English Edition)

Özet Ek Bilgiler

Introduction: Sacubitril/valsartan reduces cardiovascular morbidity and mortality in patients with systolic dysfunction (SD). The aim of the present study was to assess the evolution of chronic kidney disease (CKD) patients after initiating sacubitril/valsartan. Methods: We included 66 consecutive CKD patients with SD followed up in outpatient care. Patients had to meet the inclusion criteria of having a New York Heart Association class II to IV, receiving maximum tolerated doses of optimal medical therapy and CKD stages 1–4. At baseline, comorbidities and epidemiological data were collected and low doses of sacubitril/valsartan were initiated. At month 1 and 3, doses of sacubitril/valsartan were increased up to the maximum doses if tolerated. In each visit, renal function and cardiac biomarkers were recorded. All the data were analyzed at the end of follow up (6 months). Results: Of the 66 patients, 42 (63 %) were men, with a mean age of 73 ± 15 years. Mean creatinine at baseline was 1.42 ± 0.5 mg/dl (glomerular filtration rate (GFR) estimated by CKD-EPI was 50 ± 19 ml/min/1.73 m2) and mean left ventricular ejection fraction (LVEF) was 31 ± 9 %. At the end of follow up, LVEF improved from 31 ± 9%–39 ± 15 % (p < 0.001). After one month of treatment, renal function improved up to 53 ± 21 ml/min/1.73 m2, p = 0.005. For the remaining follow-up time, GFR remained stable (mean at end of follow-up 51 ± 18 ml/min/1.73 m2). Seven patients (10.6 %) withdrew from treatment. Conclusion: In our experience, sacubitril/Valsartan is safe in CKD, offering stability in CKD progression after 6 months. Resumen: Antecedentes y objetivo: Sacubitrilo/valsartan ha demostrado ser eficaz en la reducción de la morbi-mortalidad cardiovascular en los pacientes con disfunción sistólica (DS). El objetivo del presente estudio fue analizar la evolución de pacientes con enfermedad renal crónica (ERC) tras el inicio de sacubitril/valsartán. Material y métodos: Se incluyó a 66 pacientes consecutivos que acudieron a las consultas externas de Nefrología, con ERC y DS. Los criterios de inclusión fueron: presentar una clase funcional II a IV de la New York Heart Association (NYHA) con el tratamiento médico optimizado y ERC estadios 1 a 4. Se recogieron datos basales epidemiológicos y de comorbilidad en el momento de inicio del fármaco. En los meses 1 y 3 se tituló la dosis de sacubitril/valsartán (en función de la tolerancia). En cada visita se recogieron datos analíticos de función renal y biomarcadores cardiacos, entre otros. Se analizaron los datos a los 6 meses (fin del seguimiento). Resultados: De los 66 pacientes, 42 eran varones (63%) con una edad media 73 ± 15 años. La creatinina media fue de 1,42 ± 0,5 mg/dL (filtrado glomerular CKD-EPI 50 ± 19 ml/min/1,73 m2) con una fracción de eyección del ventrículo izquierdo (FEVI) media de 31 ± 9. Al final del seguimiento, la FEVI mejoró significativamente (basal 31 ± 9 vs final 39 ± 15, p < 0,001). En cuanto a la función renal, el filtrado glomerular por CKD-EPI presentó mejoría al mes (50 ± 19 vs 53 ± 21 ml/min/1,73 m2, p = 0,005) que se mantuvo estable (filtrado glomerular al final del seguimiento 51 ± 18 ml/min/1,73 m2). Abandonaron el tratamiento 7 pacientes (10.6%). Conclusión: En nuestra experiencia, sacubitril/valsartán es seguro en los pacientes con insuficiencia renal crónica y estabiliza la función renal a los 6 meses. Keywords: Chronic kidney disease, Heart failure, Renal failure, Sacubitril/valsartan, Palabras clave: Enfermedad renal crónica, Insuficiencia cardiaca, Insuficiencia renal, Sacubitrilo/Valsartán

ISSN: 2013-2514
Cilt: 39
Sayı: 6
Sayfa: 646 - 652

8

Lupus anticoagulant-hypoprothrombinemia syndrome: A rare association in systemic lupus erythematosus

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Gonzalo Carreño-Tarragona , Enrique Morales , María Carmen Jiménez-Herrero , Elena Cortés-Fornieles , Eduardo Gutierrez , Manuel Praga

Yıl :

2016

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2015.11.008

ISSN: 2013-2514
Cilt: 36
Sayı: 2
Sayfa: 186 - 188

Sınıflandırma :

Romatoloji %100

9

Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Ana Elena Rodríguez-Rodríguez , Javier Triñanes , Esteban Porrini , Silvia Velázquez-García , Cecilia Fumero , María Jose Vega-Prieto , María Luisa Díez-Fuentes , Sergio Luis Lima , Eduardo Salido , Armando Torres

Yıl :

2015

Nefrología (English Edition)

Piri Tam Metin Bulucu Özet Ek Bilgiler

Background: Switching to cyclosporin A may result in a reversion of tacrolimus-induced diabetes mellitus. However, mechanisms underlying such a reversion are still unknown. Methods: Obese Zucker rats were used as a model for tacrolimus-induced diabetes mellitus. A cohort of 44 obese Zucker rats received tacrolimus for 11 days (0.3 mg/kg/day) until diabetes development; then, (a) 22 rats were euthanized at day 12 and were used as a reference group (tacrolimus-day 12), and (b) 22 rats on tacrolimus were shifted to cyclosporin (2.5 mg/kg/day) for 5 days (tacrolimus-cyclosporin). An additional cohort of 22 obese Zucker rats received the vehicle for 17 days and was used as a control group. All animals underwent an intraperitoneal glucose tolerance test at the end of the study. Results: β-Cell proliferation, apoptosis and Ins2 gene expression were evaluated. Compared to rats in tacrolimus-day 12 group, those in tacrolimus-cyclosporin group showed a significant improvement in blood glucose levels in all assessment points in intraperitoneal glucose tolerance test. Diabetes decreased from 100% in tacrolimus-day-12 group to 50% in tacrolimus-cyclosporin group. Compared to tacrolimus-day-12 group, rats in tacrolimus-cyclosporin group showed an increased β-cell proliferation, but such an increase was lower than in rats receiving the vehicle. Ins2 gene expressions in rats receiving tacrolimus-cyclosporin and rats receiving the vehicle were comparable. Conclusion: An early switch from tacrolimus to cyclosporin in tacrolimus-induced diabetes mellitus resulted in an increased β-cell proliferation and reversion of diabetes in 50% of cases.

DOI : 10.1016/j.nefroe.2015.06.006

Anahtar Kelimeler : Post-transplant diabetes mellitus, Tacrolimus, Cyclosporin A

ISSN: 2013-2514
Cilt: 35
Sayı: 3
Sayfa: 264 - 272

Sınıflandırma :

Biyotıp %100

Farmakoloji ve Toksikoloji %46

Geriatrik Psikiyatri %34

10

An uncommon cause of spontaneous hemoperitoneum in a peritoneal dialysis patient

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Carlos Hidalgo-Ordoñez , Emilio Sánchez-Alvarez , Carmen Rodríguez-Suárez

Yıl :

2016

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2016.03.001

ISSN: 2013-2514
Cilt: 36
Sayı: 1
Sayfa: 80 - 81

Sınıflandırma :

Nefroloji %100

11

Renal damage secondary to checkpoint inhibitors

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Candela Moliz , Teresa Cavero , Enrique Morales , Eduardo Gutiérrez , Marina Alonso , Manuel Praga

Yıl :

2020

Nefrología (English Edition)

Ek Bilgiler

ISSN: 2013-2514
Cilt: 40
Sayı: 2
Sayfa: 206 - 208

Sınıflandırma :

Tıp ve Halk Sağlığı %90

Onkoloji %30

Nefroloji %26

12

Berardinelli-Seip syndrome in peritoneal dialysis

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

José Joaquín Bande-Fernández , Raúl García-Castro , José Emilio Sánchez-Alvarez , Carmen Rodríguez-Suárez , Diego Coronel-Aguilar , Carlos Hidalgo , Beatriz Istanbuli , Carmen Merino-Bueno , Laura del Rio-García

Yıl :

2015

Nefrología (English Edition)

Piri Tam Metin Bulucu Özet Ek Bilgiler

A case of Berardinelli-Seip syndrome, a congenital generalised lipodystrophy, is reported. Symptoms first appeared when the patient was 20 years old. She showed severe insulin resistance as well as micro- and macro-angiopathic complications, including chronic kidney disease, which required renal replacement therapy with peritoneal dialysis. The patient's clinical course was reviewed since paediatric age (when initial signs of the disease being already evident) to present time. Berardinelli-Seip syndrome is very uncommon, and the present case is particularly rare because it is the only case (at least as reported in the literature) in a patient receiving dialysis.

DOI : 10.1016/j.nefroe.2015.11.005

Anahtar Kelimeler : Berardinelli-Seip syndrome, Chronic kidney disease, Diabetic nephropathy, Peritoneal dialysis

ISSN: 2013-2514
Cilt: 35
Sayı: 5
Sayfa: 493 - 496

Sınıflandırma :

Nefroloji %100

13

Serum levels of the adipomyokine irisin in patients with chronic kidney disease

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Ana Rodríguez-Carmona , Miguel Pérez Fontán , Susana Sangiao Alvarellos , Teresa García Falcón , María Lara Pena Bello , Andrés López Muñiz , Fernando Cordido

Yıl :

2016

Nefrología (English Edition)

Piri Tam Metin Bulucu Özet Ek Bilgiler

Background: Irisin is an adipomyokine with claimed anti-obesity and anti-diabetic effects. This hormone has been insufficiently studied in patients with advanced chronic kidney disease (CKD). Objective: To perform an exploratory analysis of serum irisin levels in patients undergoing different CKD treatments. Method: Following a cross-sectional design, we estimated serum levels of irisin in 95 patients with CKD managed conservatively (advanced CKD), with peritoneal dialysis (PD) or with haemodialysis, and compared our findings with a control group of 40 healthy individuals. We investigated the correlations between serum irisin and demographic, clinical, body composition and metabolic variables. Results: Irisin levels were lower in all the CKD groups than in the control group. The univariate analysis revealed limited correlations between irisin, on the one hand, and fat (but not lean) mass, glomerular filtration rate (GFR) and plasma albumin and bicarbonate, on the other. The multivariate analysis confirmed that advanced CKD patients managed conservatively (difference 111.1 ng/mL), with PD (25.9 ng/mL) or haemodialysis (61.4 ng/mL) (all p < .0005) presented lower irisin levels than the control group. Furthermore, PD patients presented higher serum levels of irisin than those on haemodialysis (difference 39.4 ng/mL, p = .002) or those managed conservatively (24.4 ng/mL, p = .036). The multivariate analysis also identified plasma bicarbonate (B = 3.90 per mM/l, p = .001) and GFR (B = 1.89 per mL/min, p = .003) as independent predictors of irisin levels. Conversely, no adjusted correlation between irisin and body composition markers was found. Conclusions: Serum irisin levels are low in patients with CKD and show a consistent correlation with GFR and plasma bicarbonate levels. PD patients present higher levels of irisin than those managed conservatively or with haemodialysis. Our study confirms a general inconsistency of the association between serum irisin levels, on the one hand, and body composition and metabolic markers, on the other.

DOI : 10.1016/j.nefroe.2016.11.011

Anahtar Kelimeler : Irisin, Chronic kidney disease, Glomerular filtration rate, Peritoneal dialysis, Haemodialysis, Bicarbonate

ISSN: 2013-2514
Cilt: 36
Sayı: 5
Sayfa: 496 - 502

14

Benefits of a low intensity exercise programme during haemodialysis sessions in elderly patients

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Vicent Esteve Simo , Anna Junqué Jiménez , Fátima Moreno Guzmán , José Carneiro Oliveira , Miquel Fulquet Nicolas , Mónica Pou Potau , Anna Saurina Sole , Verónica Duarte Gallego , Irati Tapia Gonzalez , Manel Ramirez de Arellano

Yıl :

2015

Nefrología (English Edition)

Piri Tam Metin Bulucu Özet Ek Bilgiler

Background: Elderly patients on haemodialysis (HD) are a steadily increasing group. They show a high complexity, dependency and comorbidity. Multiple benefits from exercise in HD patients have been reported; however, they have not been specifically evaluated in an elderly population. Objective: To assess the effect of an adapted low intensity intradialytic exercise programme on muscle strength, functional capacity and health-related quality of life in our elderly patients (>80 years) on HD. Materials and methods: HD patients were non-randomly assigned to an exercise training group (E) or a control group (C) in a 12-week single-centre prospective study. E included a combined exercise programme using balls, weights, elastic bands and cycle movements in the first 2 h of HD sessions. C group patients received standard HD care. Endpoints were: (1) main biochemical data; (2) maximum quadriceps length strength (MQLS) and hand-grip (HG); (3) functional capacity tests: “Sit to stand to sit” (STS10) and “6-min walking test” (6MWT); (4) Beck Depressive Inventory (BDI); and (5) health-related quality of life questionnaire: EuroQol-5D (EQ-5D). Results: A total of 22 patients were included (50% men). Mean age was 83.2 years; patients had received HD for 44.1 months. Charlson index was 9.5. Main aetiology was diabetes mellitus (36.4%). Eleven patients were assigned to E group and 11 to C group. No related adverse effects were observed. At the end of the study, E group showed an overall improvement in tests (*p < 0.05): MQLS 10.5 ± 7.6 vs. 12.9 ± 10.1 kg, HG* 16.6 ± 8.7 vs. 18.2 ± 8.9 kg, STS10* 29.9 ± 10.6 vs. 25 ± 7.87 s, 6MWT* 14.6%, 234.4 vs. 274.7 m, BDI* 14.4 ± 11.5 vs. 11.7 ± 10.8 and EQ-5D 49 ± 19.1 vs. 59.5 ± 20.3. No similar changes were observed in C group. Significant differences between groups were also found for HG, MQLS, STS10, 6MWT, BDI and EQ-5D. No significant changes were found in biochemical and anthropometric data, antidepressant treatment or suitable dialysis parameters at the end of the study. Conclusions: (1) An adapted low intensity exercise programme improved muscle strength, functional capacity and health-related quality of life in our elderly patients on HD. (2) Our results highlight the benefits from exercise in HD patients even in this elderly population. (3) In elderly patients on HD, it is worth considering an adapted low intensity intradialytic exercise programme as a part of a comprehensive care.

DOI : 10.1016/j.nefroe.2015.03.005

Anahtar Kelimeler : Exercise, Elderly, Haemodialysis

ISSN: 2013-2514
Cilt: 35
Sayı: 4
Sayfa: 385 - 394

Sınıflandırma :

Nefroloji %44

Kardiyoloji %21

15

Congenital nephrotic syndrome secondary to pertussis

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Mervan Bekdas , Recep Eroz , Busra Cihan

Yıl :

2020

Nefrología (English Edition)

Ek Bilgiler

ISSN: 2013-2514
Cilt: 40
Sayı: 2
Sayfa: 205 - 206

Sınıflandırma :

Pediatri %93

16

A comparison of cyclophosphamide versus tacrolimus in terms of treatment effect for idiopathic membranous nephropathy: A meta-analysis

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Yan-Chun Li , Jing Huang , Xin Li , Su-Mei Zhao

Yıl :

2019

Nefrología (English Edition)

Özet Ek Bilgiler

Background and aims: Idiopathic membranous nephropathy (IMN), which is considered one of the most common causes of nephrotic syndrome in adult patients, is frequently managed with immunosuppressive agents. Both tacrolimus (TAC) and cyclophosphamide (CTX) are recommended as immunosuppressive agents in the management of IMN. However, profound effects and moderate evidence on the two drugs remains poorly defined at this period. The meta-analysis aims to summarize current best evidence on the efficacy as well as safety of TAC and CTX among IMN patients. Methods: We searched the publications on comparison of the safety and efficacy of TAC versus CTX for IMN up to April 2018. After rigorous reviewing on the quality, the data was extracted from eligible trials. All trials analyzed the summary hazard ratios (HRs) of the endpoints of interest. Results: Moderate-strong evidence indicated that tacrolimus and cyclophosphamide had comparable effects on remission rate (either CR or PR) (p > 0.05). No significant differences were found in the following parameters: the rates of diarrhea, glucose intolerance (or diabetes mellitus), gastrointestinal syndrome, as well as hypertension because of adverse effects (p > 0.05). However, patients with TAC therapy had a higher chance to develop urinary tract infection (p = 0.010) and tremor (p = 0.006). Additionally, remarkably higher risk existed in leukopenia among the CTX group as compared with the TAC group (p = 0.03). Conclusion: This meta-analysis presents a comprehensive assessment of current available evidence for the therapy of IMN, indicating a comparable remission rate with both TAC and CTX, while the long-term effects are needed for further verification. Nevertheless, different adverse effect profiles of two groups need careful consideration. Remarkably higher rates of urinary tract infection and tremor were observed among TAC group, while higher risk of leukopenia was found among CTX group. Further research into the treatment efficacy of both drugs is warranted to confirm the present conclusions. Resumen: Antecedentes y objetivos: La nefropatía membranosa idiopática (NMI), que se considera una de las causas más comunes del síndrome nefrótico en pacientes adultos, se trata con frecuencia con inmunodepresores. Tanto el tacrolimus (TAC) como la ciclofosfamida (CTX) se recomiendan como inmunosupresores en el tratamiento de la NMI. Sin embargo, los efectos profundos y la evidencia moderada de los 2 fármacos continúan estando mal definidas en este período. El metaanálisis pretende resumir la mejor evidencia actual sobre la eficacia y la seguridad del TAC y la CTX entre los pacientes con NMI. Métodos: Se realizaron búsquedas de publicaciones sobre comparación de seguridad y eficacia del TAC frente a la CTX para la NMI hasta abril de 2018. Después de una revisión rigurosa de la calidad, los datos se extrajeron de los ensayos idóneos. Todos los ensayos analizaron los cocientes de riesgo instantáneos resumidos de los criterios de valoración de interés. Resultados: La evidencia moderada-sólida indicó que el TAC y la CTX tuvieron efectos comparables en la tasa de remisión (remisión completa o remisión parcial) (p > 0,05). No se encontraron diferencias importantes en los siguientes parámetros: tasas de diarrea, intolerancia a la glucosa (o diabetes mellitus), síndrome gastrointestinal, así como hipertensión por efectos adversos (p > 0,05). Sin embargo, los pacientes con TAC como tratamiento tuvieron mayor probabilidad de desarrollar infección urinaria (p = 0,010) y temblor (p = 0,006). Además, existía un riesgo notablemente mayor de leucopenia entre el grupo que tomaba CTX que en el grupo que tomaba TAC (p = 0,03). Conclusión: Este metaanálisis presenta una evaluación exhaustiva de la evidencia disponible actualmente sobre el tratamiento de la NMI, que indica una tasa de remisión comparable con TAC y CTX, mientras que los efectos a largo plazo son necesarios para una comprobación adicional. Sin embargo, el perfil de diferentes efectos adversos de 2 grupos debe considerarse cuidadosamente. Se observaron tasas notablemente más altas de infección urinaria y temblor entre el grupo que tomaba TAC, mientras que se encontró mayor riesgo de leucopenia entre el grupo que tomaba CTX. Es necesaria investigación adicional sobre la eficacia del tratamiento de ambos fármacos para confirmar las conclusiones actuales. Keywords: Tacrolimus, Cyclophosphamide, Idiopathic membranous nephropathy, Meta-analysis, Palabras clave: Tacrolimus, Ciclofosfamida, Nefropatía membranosa idiopática, Metaanálisis

ISSN: 2013-2514
Cilt: 39
Sayı: 3
Sayfa: 269 - 276

Sınıflandırma :

Biyotıp %50

Epidemiyoloji %90

Tıp ve Halk Sağlığı %50

Nefroloji %81

17

Cardiovascular risk prediction in chronic kidney disease patients

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Santiago Cedeño Mora , Marian Goicoechea , Esther Torres , Úrsula Verdalles , Ana Pérez de José , Eduardo Verde , Soledad García de Vinuesa , José Luño

Yıl :

2017

Nefrología (English Edition)

Piri Tam Metin Bulucu Özet Ek Bilgiler

Introduction: Scores underestimate the prediction of cardiovascular risk (CVR) as they are not validated in patients with chronic kidney disease (CKD). Two of the most commonly used scores are the Framingham Risk Score (FRS-CVD) and the ASCVD (AHA/ACC 2013). The aim of this study is to evaluate the predictive ability of experiencing a cardiovascular event (CVE) via these 2 scores in the CKD population. Material and methods: Prospective, observational study of 400 prevalent patients with CKD (stages 1–4 according the KDOQI; not on dialysis). Cardiovascular risk was calculated according to the 2 scores and the predictive capacity of cardiovascular events (atherosclerotic events:myocardial infarction, ischaemic and haemorrhagic stroke, peripheral vascular disease; and non-atherosclerotic events: heart failure) was analysed. Results: Forty-nine atherosclerotic cardiovascular events occurred in 40.3 ± 6.6 months of follow-up. Most of the patients were classified as high CVR by both scores (59% by the FRS-CVD and 75% by the ASCVD). All cardiovascular events occurred in the high CVR patients and both scores (FRS-CVD log-rank 12.2, P < 0.001, HR 3.1 [95% CI: 1.3–7.1] P: 0.006 and ASCVD log-rank 8.5 P < 0.001, HR 3.2 [95% CI: 1.1–9.4] P: 0.03) were independent predictors adjusted to renal function, albuminuria and previous cardiovascular events. Conclusion: The cardiovascular risk scores (FRS-CVD and ASCVD [AHA/ACC 2013]) can estimate the probability of atherosclerotic cardiovascular events in patients with CKD regardless of renal function, albuminuria and previous cardiovascular events.

DOI : 10.1016/j.nefroe.2017.03.005

Anahtar Kelimeler : Chronic kidney disease, Cardiovascular risk, Cardiovascular risk score, FRS-CVD, ASCVD

ISSN: 2013-2514
Cilt: 37
Sayı: 3
Sayfa: 293 - 300

18

Response to acetazolamide in a patient with tumoural calcinosis

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Venecia Landini-Enríquez , Marco Antonio Escamilla , Elena Soto-Vega , Karen Chamizo-Aguilar

Yıl :

2015

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2015.11.003

ISSN: 2013-2514
Cilt: 35
Sayı: 5
Sayfa: 503 - 505

Sınıflandırma :

Tıp ve Halk Sağlığı %90

Farmakoterapi %56

19

Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin–angiotensin–aldosterone system among patients with obesity and proteinuria

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Enrique Morales , Eduardo Gutiérrez , Jara Caro , Angel Sevillano , Jorge Rojas-Rivera , Manuel Praga

Yıl :

2015

Nefrología (English Edition)

Piri Tam Metin Bulucu Özet Ek Bilgiler

Introduction: Over the past decade, obesity has become a risk factor for developing chronic kidney disease. Proteinuria is known to be an independent determinant of the progression of chronic kidney disease, and adipose tissue is a recognized source of components of the renin–angiotensin–aldosterone system (RAAS). Recent studies have shown that plasma aldosterone levels are disproportionately higher in patients with obesity. Drugs that block the RAAS are unable to inhibit aldosterone in the long term. The aim of our study was to analyze the renoprotective effect of an aldosterone antagonist in combination with RAAS blockers in patients with obesity and proteinuric nephropathy. Material and methods: This study is a substudy of previously published study on the renoprotective effect of mineralocorticoid receptor blockers in patients with proteinuric nephropathies. Patients with proteinuria levels >1 g/24 h who were taking spironolactone and were being treated with other RAAS blockers were divided according to body mass index (BMI) into an obesity group (BMI ≥30 kg/m2) and a control group. Results: Seventy-one patients were included in the study, with a mean age of 56.7 ± 15.1 years. More than 50% of the patients in both groups had diabetes. Thirty-two patients were included in the obesity group and 39 were included in the control group. There were no significant differences in renal function, proteinuria, blood pressure, serum potassium levels and the percentage of RAAS blockers in both groups. After a follow-up of 28.9 (14–84) months, there was a 59.4% reduction in proteinuria in the obesity group (2.8 ± 2.1 vs. 1.3 ± 1.6 g/24 h, p < .05). The reduction in proteinuria was greater than 50% in 22 (68.8%) cases, and the mean blood pressure showed a significant decrease (from 100.6 ± 9 to 92.1 ± 7.4 mm Hg, p < .05). The control group showed a 69.6% reduction in proteinuria (1.9 ± 1.4 to 0.8 ± 0.5, p < 0.05). The reduction of proteinuria was higher than 50% in 22 (68.8%) cases in obese patients and in 33 (84.6%) cases in non-obese group. Renal function remained stable in both groups during the follow-up. Nine patients (28.1%) in the obesity group experienced gynecomastia. The incidence of hyperkalemia was similar for the 2 groups (6.3%). Conclusion: Aldosterone antagonist treatment in obese patients with proteinuric nephropathies induces a drastic and sustained reduction in proteinuria but not more than the non-obese group. There was a trend toward slowing progression of renal failure with few adverse events.

DOI : 10.1016/j.nefroe.2015.11.007

Anahtar Kelimeler : Obesity, Aldosterone antagonist, Proteinuria, Nephropathy

ISSN: 2013-2514
Cilt: 35
Sayı: 6
Sayfa: 554 - 561

Sınıflandırma :

Nefroloji %74

20

Low triiodothyronine is associated with elevation of N-terminal pro-brain natriuretic peptide (NT-proBNP) and mortality in dialysis patients

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

María del Carmen Prado-Uribe , María-de-Jesús Ventura , Marcela Ávila-Díaz , Carmen J. Mora , Antonio Méndez-Durán , Diana Villanueva-Noches , Alejandra Cisneros , Begoña Ilabaca , Alfonso Cueto-Manzano , Fernando García-Contreras , Bengt Lindholm , Elvia García-López , Ramón Paniagua

Yıl :

2017

Nefrología (English Edition)

Özet Ek Bilgiler

Background: Low thyroid hormone (TH) levels and myocardial damage are common in dialysis patients and are associated with mortality. However, little is known about the role of THs on myocardial damage as has been described in primary thyroid diseases. The aim of this study was to explore the potential relationship between low total triiodothyronine (total T3) and biomarkers of myocardial damage and the effect of their interaction on mortality, to ascertain if cardiovascular damage is the link between low THs and the risk of death in dialysis patients with CKD. Material and methods: TH plasma levels, nutritional markers, inflammation and myocardial damage were studied in 296 patients undergoing peritoneal dialysis or haemodialysis, who were followed up for 16 months to ascertain the association between biochemical variables and mortality. Results: Low total T3 levels were found in 45% of patients, which was inversely correlated with C-reactive protein (CRP) and NT-proBNP, and directly correlated with albumin and transferrin. Diabetes, CRP and total T3 were risk factors for all-cause mortality, and CRP, NT-proBNP and total T3 for cardiovascular mortality. Conclusions: Low total T3 levels are common in dialysis patients and are associated with inflammation, malnutrition and myocardial damage. The latter may be the link between low THs and all-cause and cardiovascular mortality. Resumen: Antecedentes: La disminución de hormonas tiroideas (HT) y el daño miocárdico son frecuentes en pacientes en diálisis y están asociados con la mortalidad. Sin embargo, poco se conoce de la importancia de las HT como factor de daño miocárdico, como se ha descrito en las enfermedades tiroideas primarias. El objetivo de este estudio fue explorar si existe interacción entre la disminución de triyodotironina total (tT3) y los marcadores de daño miocárdico y la relación de esta interacción entre ambos con la mortalidad, para establecer si el daño cardiovascular es el vínculo entre la disminución de HT y el riesgo de muerte en pacientes con ERC en diálisis. Material y métodos: Se estudiaron los niveles plasmáticos de HT, de marcadores de nutrición, inflamación y de daño al miocardio en 296 pacientes en diálisis peritoneal o en hemodiálisis, a los que se vigiló por 16 meses para conocer la asociación de las variables bioquímicas con la mortalidad. Resultados: En el 45% de los pacientes se encontró tT3 disminuida, lo cual tuvo correlación inversa con la proteína C reactiva (PCR) y con el NT-proBNP y directa con la albúmina y la transferrina. La diabetes, la PCR y la tT3 fueron factores de riesgo para la mortalidad por cualquier causa y la PCR, el NT-proBNP y la tT3 para mortalidad cardiovascular. Conclusiones: Los niveles bajos de tT3 son frecuentes en pacientes en diálisis, se asocian con inflamación, desnutrición y daño miocárdico: este último puede ser el vínculo entre la disminución de HT y la mortalidad por cualquier causa y la mortalidad cardiovascular. Keywords: Thyroid hormones, Triiodothyronine, Hemodialysis, Peritoneal dialysis, Mortality, NT-proBNP, Palabras clave: Hormonas tiroideas, Triyodotironina, Hemodiálisis, Diálisis peritoneal, Mortalidad, NT-proBNP

ISSN: 2013-2514
Cilt: 37
Sayı: 6
Sayfa: 598 - 607

Sınıflandırma :

Nefroloji %99

21

Role of photopheresis in the treatment of refractory cellular rejection in kidney transplantation

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Ernesto José Fernández , Celia López , Ana Ramírez , Rita Guerra , Lucía López , Fernando Fernández , Manuel Tapia , César García-Cantón

Yıl :

2016

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2015.06.013

ISSN: 2013-2514
Cilt: 36
Sayı: 3
Sayfa: 327 - 328

Sınıflandırma :

Tıp ve Halk Sağlığı %89

Nakil Cerrahisi %100

22

Diarrhea and malnutrition in kidney transplant recipient: A case of infection by cryptosporidiosis

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Raquel Castellano Carrasco , M. José Torres Sánchez , Francisco Javier de Teresa Alguacil , Antonio Osuna Ortega

Yıl :

2017

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2017.05.004

ISSN: 2013-2514
Cilt: 37
Sayı: 3
Sayfa: 338 - 339

Sınıflandırma :

Tıp ve Halk Sağlığı %51

Nefroloji %74

Biyotıp %49

İlaç Direnci %22

23

Haemodialysis session: The perfect storm for vascular calcification

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Miguel Seras , Ángel Luis Martín de Francisco , Celestino Piñera , Simón Gundin , Marta García-Unzueta , Maria Kislikova , Zoila Albines , Mara Serrano , Manuel Arias

Yıl :

2015

Nefrología (English Edition)

Piri Tam Metin Bulucu Özet Ek Bilgiler

Introduction: Vascular calcification (VC) associated to chronic kidney disease (CKD) is a complex phenomenon closely related to mineral bone metabolism disorders. Many are the factors implicated, as the drugs used in the treatment of CKD. Some in vitro studies suggest that electrolyte and acid–base disorders induced by haemodialysis (HD) may play a key role in VC. Methods: We analysed electrolyte and acid–base disorders that occur during an HD session in 26 patients randomly assigned to 1.25 mM or 1.5 mM calcium bath. Results: There is a calcium load in all the patients, independently of calcium bath concentration or basal serum calcium levels. At the end of the session, 100% of the patients dialysed with 1.5 mM calcium bath have calcium serum levels >1.3 mM. However, this only occurs in 15% of the patients dialysed with 1.25 mM calcium bath. During this calcium load, phosphorus levels persist uncontrolled. Besides, there is a progressive alkalinisation in all the patients. In the end of the session 50% have serum bicarbonate >30 mM and 23% pH >7.5. Conclusions: During HD sessions occur electrolyte and acid–base disorders that induce VC: calcium load and alkalisation in presence of elevated phosphorus levels. It is necessary to perform studies with kinetic models of calcium load and alkalinisation different from the actual ones.

DOI : 10.1016/j.nefroe.2015.09.008

Anahtar Kelimeler : Vascular calcification, Chronic kidney disease, Haemodialysis

ISSN: 2013-2514
Cilt: 35
Sayı: 5
Sayfa: 448 - 456

Sınıflandırma :

Tıp ve Halk Sağlığı %92

Nefroloji %100

24

Our experience in emergency treatment of renal haemorrhage

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Cristina Pantoja Peralta , Almudena Badenes Gallardo , Raúl García Vidal , Natalia Rodríguez Espinosa , Francesc Pañella Agustí , Benet Gómez Moya

Yıl :

2019

Nefrología (English Edition)

Özet Ek Bilgiler

Introduction: Renal haemorrhage is a potentially life-threatening event requiring emergency surgery. Endovascular therapy is currently the first-line treatment option. Objectives: Review patients with renal haemorrhage who required emergency endovascular therapy at our centre. Evaluate the causes of the bleeding, the treatment performed and the clinical outcomes. Material and methods: We performed a retrospective analysis of consecutive patients with renal bleeding who underwent endovascular therapy from June 2012 to June 2017 at Hospital Universitari Joan XXIII (Tarragona, Spain). Demographic data (age, gender and comorbidity) and other related variables were collected (mechanism of injury, haemodynamic stability and anticoagulant therapy). We also studied the CT angiography findings, time from diagnosis to surgery, endovascular technique and materials used, extent of tissue embolised and outcomes. Results: Twenty-two (22) patients were included with a mean age of 63 (range 19–85). The aetiology of injuries included: renal biopsy (n = 7, 31.8%), bleeding from malignant kidney tumour (n = 5, 22.7%), trauma (n = 4, 18.2%), angiomyolipoma (n = 2, 9.1%), spontaneous bleeding (n = 2, 9.1%) and surgical complications (n = 2, 9.1%). The endovascular therapy technique was embolisation in all cases. The following materials were used: spheres (9.1%); coils (63.6%); spheres + coils (18.2%); and spheres + plug (9.1%). In 17 cases (77.3%), selective embolisation was performed and in five cases (22.7%), embolisation of the whole kidney. Clinical and technical success rates of 100% were recorded. The 30-day mortality rate was 9.1%. Conclusion: We believe that endovascular therapy is an effective modality for the management of renal bleeding which, in many cases, enables a large part of the renal tissue to be preserved. Resumen: Introducción: Los casos de hemorragia renal que provocan un compromiso para la vida del paciente requieren de una cirugía urgente. Actualmente la cirugía endovascular es el tratamiento de primera elección. Objetivo: Revisar los pacientes con una hemorragia renal que fueron intervenidos de urgencia mediante una técnica endovascular en nuestro centro. Evaluar las causas de sangrado renal, el tratamiento realizado así como los resultados obtenidos. Material y métodos: Realizamos un estudio retrospectivo de pacientes consecutivos con sangrado renal y que fueron tratados con una técnica endovascular entre junio del 2012 y junio del 2017 en el Hospital Universitari Joan XXIII (Tarragona). Se recogieron los datos demográficos (edad, sexo, comorbilidad) y otras variables relacionadas (mecanismo de la lesión, la estabilidad hemodinámica y si estaba en tratamiento anticoagulante). También se analizaron los hallazgos encontrados en la angio-TAC, el tiempo transcurrido entre el diagnóstico y la realización de la cirugía, la técnica endovascular y el material utilizado, la extensión de parénquima embolizado y los resultados obtenidos. Resultados: Incluimos a 22 pacientes con una edad media de 63 años (19-85). Las causas de lesión fueron relacionadas con punción de una biopsia renal (n=7,31; 8%), sangrado de tumoraciones malignas renales (n=5; 22,7%), traumatismos (n=4; 18,2%), angiomiolipomas (n=2; 9,1%), sangrado espontáneo (n=2; 9,1%) y complicaciones quirúrgicas (n=2; 9,1%). En todos los casos la técnica endovascular realizada fue la embolización. El material utilizado fue: esferas (9,1%), coils (63,6%), esferas + coils (18,2%), esferas+oclusor (9,1%). En 17 de los casos (77,3%) se llevó a cabo una embolización selectiva y en 5 casos (22,7%) una embolización de todo el riñón. El éxito clínico y técnico fue del 100%. La mortalidad a los 30 días fue del 9,1%. Conclusión: Creemos que el tratamiento endovascular es una técnica efectiva para el control del sangrado renal y permite, en la mayoría de casos, la preservación de gran parte de parénquima renal. Keywords: Embolisation, Haemorrhage, Kidney, Renal artery, Palabras clave: Embolización, Hemorragia, Riñón, Arteria renal

ISSN: 2013-2514
Cilt: 39
Sayı: 3
Sayfa: 301 - 308

Sınıflandırma :

Minimal İnvaziv Cerrahi %36

25

Thermal disinfection in hemodialysis using the A0 concept as dispenser

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Néstor Gabriel Toapanta Gaibor , Luis Gil Sacaluga , Francisco de la Cerda Ojeda , José Ramón Molas Cotén , Mercedes Salgueira Lazo

Yıl :

2019

Nefrología (English Edition)

Özet Ek Bilgiler

Patients with chronic kidney disease in the hemodialysis program are exposed to large amounts of water, as this constitutes about 96% of the dialysis fluid. It is known that the use of better quality water decreases the state of chronic inflammation in dialysis patients. Disinfection as part of water treatment plays an important role in meeting the established quality standards; currently, heat disinfection is highly recommended, however the dose of it is not clearly established in the literature. The objective of this review is to know what is available in the literature on the dose of heat disinfection that should be used in hemodialysis and to present our experience with this method at a set dose of 12.000 A0. Resumen: Los pacientes con enfermedad renal crónica en programa de hemodiálisis se encuentran expuestos a grandes cantidades de agua ya que este constituye cerca del 96% del líquido de diálisis. Es conocido que el uso de agua de mejor calidad disminuye el estado de inflamación crónica en los pacientes en diálisis. La desinfección como parte del tratamiento del agua tiene un papel importante para cumplir los estándares de calidad establecidos; actualmente la desinfección por calor es altamente recomendable, sin embargo, la dosis de la misma no está claramente establecida en la literatura. El objetivo de esta revisión es conocer lo disponible en la literatura sobre la dosis de desinfección por calor que se debe utilizar en hemodiálisis, así como presentar nuestra experiencia con este método a una dosis establecida de 12.000 A0. Keywords: Thermal disinfection, Heat disinfection, Hemodialysis, Endotoxins, Concept A0, Palabras clave: Desinfección térmica, Hemodiálisis, Endotoxinas, Concepto A0

ISSN: 2013-2514
Cilt: 39
Sayı: 5
Sayfa: 482 - 488

26

Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Jordi Bover , Pablo Ureña-Torres , José Luis Górriz , María Jesús Lloret , Iara da Silva , César Ruiz-García , Pamela Chang , Mariano Rodríguez , José Ballarín

Yıl :

2016

Nefrología (English Edition)

Piri Tam Metin Bulucu Özet Ek Bilgiler

Cardiovascular (CV) calcification is a highly prevalent condition at all stages of chronic kidney disease (CKD) and is directly associated with increased CV and global morbidity and mortality. In the first part of this review, we have shown that CV calcifications represent an important part of the CKD–MBD complex and are a superior predictor of clinical outcomes in our patients. However, it is also necessary to demonstrate that CV calcification is a modifiable risk factor including the possibility of decreasing (or at least not aggravating) its progression with iatrogenic manoeuvres. Although, strictly speaking, only circumstantial evidence is available, it is known that certain drugs may modify the progression of CV calcifications, even though a direct causal link with improved survival has not been demonstrated. For example, non-calcium-based phosphate binders demonstrated the ability to attenuate the progression of CV calcification compared with the liberal use of calcium-based phosphate binders in several randomised clinical trials. Moreover, although only in experimental conditions, selective activators of the vitamin D receptor seem to have a wider therapeutic margin against CV calcification. Finally, calcimimetics seem to attenuate the progression of CV calcification in dialysis patients. While new therapeutic strategies are being developed (i.e. vitamin K, SNF472, etc.), we suggest that the evaluation of CV calcifications could be a diagnostic tool used by nephrologists to personalise their therapeutic decisions.

DOI : 10.1016/j.nefroe.2016.12.011

Anahtar Kelimeler : Chronic kidney disease, Vascular calcification, Chronic kidney diseaseu2013mineral and bone disorders, Phosphate, Vitamin D, Calcimimetics, Calciphylaxis

ISSN: 2013-2514
Cilt: 36
Sayı: 6
Sayfa: 597 - 608

Sınıflandırma :

Nefroloji %46

Anjiyoloji %39

27

Lengthening time to hemostasis in hemodialysis. Factor XI deficiency (hemophilia C): A case report

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Francisco Valga , Tania Monzón , Fernando Henriquez Palop , Gloria Antón

Yıl :

2017

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2017.04.017

ISSN: 2013-2514
Cilt: 37
Sayı: 5
Sayfa: 544 - 545

Sınıflandırma :

Kan Transfüzyon Tıbbı %99

28

Acute renal colic: Beyond kidney stones

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Sandra Silva , Martinho Almeida , Lurdes Rodrigues , Maximino Costa

Yıl :

2016

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2016.02.001

ISSN: 2013-2514
Cilt: 36
Sayı: 2
Sayfa: 182 - 184

Sınıflandırma :

Nefroloji %97

29

Hidden renal disease in the elderly is no longer buried after 10 years of follow up

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Manuel Heras , María Teresa Guerrero , María José Fernández-Reyes , Angélica Muñoz

Yıl :

2017

Nefrología (English Edition)

Piri Tam Metin Bulucu Ek Bilgiler

DOI : 10.1016/j.nefroe.2016.10.014

ISSN: 2013-2514
Cilt: 37
Sayı: 5
Sayfa: 547 - 548

Sınıflandırma :

Tıp ve Halk Sağlığı %96

Nefroloji %54

Sağlık Bilişimi %26

30

Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients

Dergi Makalesi

Kaynak :

Directory of Open Access Journals (DOAJ)

Dergi:

Nefrología (English Edition)

Yazar(lar) :

Elena Rodríguez-Sánchez , José Alberto Navarro-García , Jennifer Aceves-Ripoll , Gloria Álvarez-Llamas , Julián Segura , María G. Barderas , Luis Miguel Ruilope , Gema Ruiz-Hurtado

Yıl :

2019

Nefrología (English Edition)

Özet Ek Bilgiler